Asparagine synthetase polymorphisms and toxicity and efficacy of asparaginases.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 25294910.
- Also identified by DOI 10.1158/1078-0432.CCR-14-1714.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Asparaginases develop innovative "tumor starvation" conditions for all antileukemia treatments; however, administrations are limited by the toxicities of this drug. Patients exhibiting moderate toxicity have optimal treatment outcomes. Certain asparagine synthetase polymorphisms may contribute to severe host toxicities in divergent subsets of patients, whereas others do not. Clinical correlations should be evaluated.
Medical subject headings
- Antineoplastic Agents
- Asparaginase
- Aspartate-Ammonia Ligase
- Precursor Cell Lymphoblastic Leukemia-Lymphoma